Zinplava™ (bezlotoxumab) – New drug approval
October 21, 2016 – Merck announced the FDA approval of Zinplava (bezlotoxumab) injection, to reduce recurrence of Clostridium difficile infection (CDI) in patients 18 years of age or older who are receiving antibacterial drug treatment of CDI and are at a high risk for CDI recurrence.
Top